Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...

The European stock markets closed lower in Monday trading as The Stoxx Europe 600 fell 1.1%, Germany's DAX dropped 1.53%, the FTSE 100 in London was down 0.78%, France's CAC 40 declined 0.69%, and the ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...